| 货号 | 16800-500ug |
| 描述 | IPI-145 is a potent inhibitor of the phosphoinositide 3-kinase (PI3K) isoforms PI3Kγ and PI3Kδ (IC50s = 0.24 and 50 nM, respectively).1 It is orally bioavailable and selective.1 As PI3Kγ and PI3Kδ are preferentially expressed in immune cells, IPI-145 has profound effects in collagen-induced and adjuvant-induced arthritis, ovalbumin-induced asthma, and systemic lupus erythematosus animal models.1,2 It also has potential applications in immunotherapy and in certain cancers.3,4 |
| 别名 | Duvelisib;INK1197; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Winkler, D.G.,Faia, K.L.,DiNitto, J.P., et al. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chemistry & Biology 20(11), 1364-1374 (2013). 2.Boyle, D.L.,Kim, H.R.,Topolewski, K., et al. Novel phosphoinositide 3-kinase δ,γ inhibitor: Potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis. Journal of Pharmacology and Experimental Therapeutics 348(2), 271-280 (2014). 3.Mockler, M.B.,Conroy, M.J., and Lysaght, J. Targeting T cell immunometabolism for cancer immunotherapy; understanding the impact of the tumor microenvironment. Front.Oncol. 4(107), 1-11 (2014). 4.Falasca, M., and Maffucci, T. Targeting p100γ in gastrointestinal cancers: Attack on multiple fronts. Front.Physiol. 5(391), 1-10 (2014). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 416.9 |
| 分子式 | C22H17ClN6O |
| CAS号 | 1201438-56-3 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |